Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, has revealed data from a Phase 2 sub-study of pemvidutide, indicating significant lean mass preservation and reduction in visceral adipose tissue (VAT) among overweight and obese individuals. The findings were presented at the European Association for the Study of Diabetes (EASD) Annual Meeting in Madrid, Spain.
The sub-study, part of the MOMENTUM obesity trial, utilized MRI to assess body composition changes in 67 subjects, 50 of whom were treated with pemvidutide over a 48-week period. Results showed a lean loss ratio of 21.9%, which measures the change in lean mass relative to total mass loss. Notably, participants over 60 years of age experienced an even lower lean loss ratio of 19.9%, highlighting the treatment's potential to mitigate risks associated with age-related frailty.
In addition to preserving lean mass, pemvidutide treatment led to a 25.6% reduction in VAT at a 2.4mg dose by the study's end. This type of adipose tissue is closely linked to cardiovascular disease risk, and its preferential reduction is seen as a positive outcome.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.